Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
Lilly buys cash-strapped Adverum for eye disease gene therapy
Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy.
James Waldron
Oct 24, 2025 9:25am
Lilly oncology head weighs in on FDA cancer drug policies
Oct 21, 2025 11:53am
Lilly pads oral GLP-1 case with pair of phase 3 diabetes wins
Oct 15, 2025 9:48am
Roche nabs FDA clearance for Alzheimer's biomarker blood test
Oct 14, 2025 11:12am
Former CBER chief Peter Marks leaps to Lilly—Chutes & Ladders
Oct 10, 2025 8:30am
Former FDA official Peter Marks joins Eli Lilly
Oct 7, 2025 3:49pm
